Abstract：Ubiquitin-specific protease 14 (USP14), a member of the ubiquitin-specific proteases family, plays an important role in the development and progression of malignant tumors through removing ubiquitin chain from substrates such as androgen receptor (AR), cell cycle-related proteins and apoptosis-related proteins to regulate protein stability and activity. The mechanisms of USP14 in a variety of malignant tumors are complex and diverse, including promotion in cell proliferation and inflammation as well as inhibition in apoptosis, autophagy, and drug resistance. Simultaneously, aberrant expression of USP14 is closely correlated with poor prognosis in most malignant tumors. Therefore, USP14 is a potential drug target for tumor therapy, and the development of its inhibitors appears as a new direction of anti-tumor drug research. Currently, specific inhibitors of USP14 mainly include IU1, its analogs (IU1-47, IU1-206, IU1-248), and b-AP15. The inhibitory ability of IU1 analogs on USP14 activity is 10 times than that of IU1, due to the difference in crystal structure. On the other hand, the inhibitors of USP14 show powerful anti-tumor effects inducing tumor cell death through a variety of signal pathways, which enables the inhibitor as potential targeted drugs. It will be extremely important to further explore the relationship between USP14 and its inhibitors in the tumor development and progression. This review summarizes the latest research of USP14 and its inhibitors, including their structures and functions in malignant tumors. Furthermore, the problems, challenges, new directions and strategies for future research, were also reviewed in current study.
杜雪花, 张晓东. USP14及其抑制剂调控肿瘤的发生与发展[J]. 中国生物化学与分子生物学报, 2021, 37(10): 1297-1304.
DU Xue-Hua, ZHANG Xiao-Dong. The Roles of USP14 and Its Inhibitors in the Occurrence and Development of Tumors. Chinese Journal of Biochemistry and Molecular Biol, 2021, 37(10): 1297-1304.
[1] Komander D, Rape M. The Ubiquitin Code[J]. Annu Rev Biochem, 2012, 81: 203-229 [2] Kulathu Y, Komander D. Atypical ubiquitylation - the unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages[J]. Nat Rev Mol Cell Biol, 2012, 13(8): 508-523 [3] Amerik AY, Hochstrasser M. Mechanism and function of deubiquitinating enzymes[J]. Biochim Biophys Acta, 2004, 1695(1-3): 189-207 [4] Wertz IE, Murray JM. Structurally-defined deubiquitinase inhibitors provide opportunities to investigate disease mechanisms[J]. Drug Discov Today Technol, 2019, 31: 109-123 [5] Kim HT, Goldberg AL. UBL domain of Usp14 and other proteins stimulates proteasome activities and protein degradation in cells[J]. Proc Natl Acad Sci U S A, 2018, 115(50): e11642-e11650 [6] Lee BH, Lee MJ, Park S, et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14[J]. Nature, 2010, 467(7312): 179-184 [7] Lee BH, Lu Y, Prado MA, et al. USP14 deubiquitinates proteasome-bound substrates that are ubiquitinated at multiple sites[J]. Nature, 2016, 532(7599): 398-401 [8] Kim HT, Goldberg AL. UBL domain of Usp14 and other proteins stimulates proteasome activities and protein degradation in cells[J]. Proc Natl Acad Sci U S A, 2018, 115(50): E11642-11650 [9] Xu D, Shan B, Lee BH, et al. Phosphorylation and activation of ubiquitin-specific protease-14 by Akt regulates the ubiquitin-proteasome system [J]. Elife, 2015, 4: e10510 [10] Yeo SK, Guan JL. Breast Cancer: Multiple Subtypes within a Tumor?[J]. Trends Cancer, 2017, 3(11): 753-760 [11] Kono M, Fujii T, Lim B, et al. Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review[J]. JAMA Oncol, 2017, 3(9): 1266-1273 [12] Ni M, Chen Y, Lim E, et al. Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer[J]. Cancer Cell, 2011, 20(1): 119-131 [13] Zhu L, Yang S, He S, et al. Downregulation of ubiquitin-specific protease 14 (USP14) inhibits breast cancer cell proliferation and metastasis, but promotes apoptosis[J]. J Mol Histol, 2016, 47(1): 69-80 [14] Xia X, Huang C, Liao Y, et al. Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide[J]. J Exp Clin Cancer Res, 2019, 38(1): 220 [15] Liao Y, Xia X, Liu N, et al. Growth arrest and apoptosis induction in androgen receptor-positive human breast cancer cells by inhibition of USP14-mediated androgen receptor deubiquitination[J]. Oncogene, 2018, 37(14): 1896-1910 [16] Liu B, Liu Y, Wang Y, et al. CyclinB1 deubiquitination by USP14 regulates cell cycle progression in breast cancer[J]. Pathol Res Pract, 2019, 215(10): 152592 [17] Du M, Yuan T, Schilter K F, et al. Prostate cancer risk locus at 8q24 as a regulatory hub by physical interactions with multiple genomic loci across the genome[J]. Hum Mol Genet, 2015, 24(1): 154-166 [18] Liao Y, Liu N, Hua X, et al. Proteasome-associated deubiquitinase ubiquitin-specific protease 14 regulates prostate cancer proliferation by deubiquitinating and stabilizing androgen receptor[J]. Cell Death Dis, 2017, 8(2): e2585 [19] Schiewer MJ, Augello MA, Knudsen KE. The AR dependent cell cycle: Mechanisms and cancer relevance[J]. Mol Cell Endocrinol, 2012, 352(1-2): 34-45 [20] Geng L, Chen X, Zhang M, et al. Ubiquitin-specific protease 14 promotes prostate cancer progression through deubiquitinating the transcriptional factor ATF2[J]. Biochem Biophys Res Commun, 2020, 524(1): 16-21 [21] Sharma A, Alswillah T, Singh K, et al. USP14 regulates DNA damage repair by targeting RNF168-dependent ubiquitination[J]. Autophagy, 2018, 14(11): 1976-1990 [22] Shen J, Hong L, Chen L. Ubiquitin-specific protease 14 regulates ovarian cancer cisplatin-resistance by stabilizing BCL6 oncoprotein[J]. Biochem Biophys Res Commun, 2020, 524(3): 683-688 [23] Luo H, Wang X, Ge H, et al. Inhibition of ubiquitin-specific protease14 promotes connexin32 -internalization and counteracts cisplatin cytotoxicity in human ovarian cancer cells [J]. Oncol Rep, 2019, 42(3):1237-1247 [24] Wang Y, Wang J, Zhong J, et al. Ubiquitin-specific protease 14 (USP14) regulates cellular proliferation and apoptosis in epithelial ovarian cancer[J]. Med Oncol, 2015, 32(1): 379 [25] Huang G, Li L, Zhou W. USP14 activation promotes tumor progression in hepatocellular carcinoma[J]. Oncol Rep, 2015, 34(6): 2917-2924 [26] Liu B, Jiang S, Li M, et al. Proteome-wide analysis of USP14 substrates revealed its role in hepatosteatosis via stabilization of FASN[J]. Nat Commun, 2018, 9(1): 4770 [27] Wu N, Liu C, Bai C, et al. Over-Expression of Deubiquitinating Enzyme USP14 in Lung Adenocarcinoma Promotes Proliferation through the Accumulation of β-Catenin[J]. Int J Mol Sci, 2013, 14(6): 10749-10760 [28] Han KH, Kwak M, Lee TH, et al. USP14 Inhibition Regulates Tumorigenesis by Inducing Autophagy in Lung Cancer In Vitro[J]. Int J Mol Sci, 2019, 20(21): 5300 [29] Wei J, Dong S, Bowser RK, et al. Regulation of the ubiquitylation and deubiquitylation of CREB-binding protein modulates histone acetylation and lung inflammation[J]. Sci Signal, 2017, 10(483): eaak9660 [30] Wang Y, Jiang Y, Ding S, et al. Small molecule inhibitors reveal allosteric regulation of USP14 via steric blockade[J]. Cell Res, 2018, 28(12): 1186-1194 [31] Chakraborty J, von Stockum S, Marchesan E, et al. USP14 inhibition corrects an in vivo model of impaired mitophagy[J]. EMBO Mol Med, 2018, 10(11): e9014 [32] Kim HT, Goldberg AL. The deubiquitinating enzyme Usp14 allosterically inhibits multiple proteasomal activities and ubiquitin-independent proteolysis[J]. J Biol Chem, 2017, 292(23): 9830-9839 [33] Kim E, Park S, Lee JH, et al. Dual Function of USP14 Deubiquitinase in Cellular Proteasomal Activity and Autophagic Flux[J]. Cell Rep, 2018, 24(3): 732-743 [34] D'Arcy P, Linder S. Proteasome deubiquitinases as novel targets for cancer therapy[J]. Int J Biochem Cell Biol, 2012, 44(11): 1729-1738 [35] Brnjic S, Mazurkiewicz M, Fryknäs M, et al. Induction of Tumor Cell Apoptosis by a Proteasome Deubiquitinase Inhibitor Is Associated with Oxidative Stress[J]. Antioxid Redox Signal, 2014, 21(17): 2271-2285 [36] Hillert EK, Brnjic S, Zhang X, et al. Proteasome inhibitor b-AP15 induces enhanced proteotoxicity by inhibiting cytoprotective aggresome formation[J]. Cancer Lett, 2019, 448: 70-83 [37] Zhang X, Pellegrini P, Saei AA, et al. The deubiquitinase inhibitor b-AP15 induces strong proteotoxic stress and mitochondrial damage[J]. Biochem Pharmacol, 2018, 156: 291-301 [38] Zhang X, Espinosa B, Saei AA, et al. Oxidative Stress Induced by the Deubiquitinase Inhibitor b-AP15 Is Associated with Mitochondrial Impairment[J]. Oxid Med Cell Longev, 2019, 2019: 1659468 [39] Sarhan D, Wennerberg E, D'Arcy P, et al. A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells[J]. Cancer Immunol Immunother, 2013, 62(8): 1359-1368 [40] Oh YT, Deng L, Deng J, et al. The proteasome deubiquitinase inhibitor b-AP15 enhances DR5 activation-induced apoptosis through stabilizing DR5[J]. Sci Rep, 2017, 7(1): 8027 [41] Ding Y, Chen X, Wang B, et al. Deubiquitinase inhibitor b-AP15 activates endoplasmic reticulum (ER) stress and inhibits Wnt/Notch1 signaling pathway leading to the reduction of cell survival in hepatocellular carcinoma cells[J]. Eur J Pharmacol, 2018, 825: 10-18 [42] Cai J, Xia X, Liao Y, et al. A novel deubiquitinase inhibitor b-AP15 triggers apoptosis in both androgen receptor-dependent and -independent prostate cancers[J]. Oncotarget, 2017, 8(38): 63232-63246 [43] Zhang F, Xu R, Chai R, et al. Deubiquitinase Inhibitor b-AP15 Attenuated LPS-Induced Inflammation via Inhibiting ERK1/2, JNK, and NF-Kappa B[J]. Front Mol Biosci, 2020, 7: 49 [44] Schmidt M, Altdörfer V, Schnitte S, et al. The Deubiquitinase Inhibitor b-AP15 and Its Effect on Phenotype and Function of Monocyte-Derived Dendritic Cells[J]. Neoplasia, 2019, 21(7): 653-664 [45] Liu N, Guo Z, Xia X, et al. Auranofin lethality to prostate cancer includes inhibition of proteasomal deubiquitinases and disrupted androgen receptor signaling[J]. Eur J Pharmacol, 2019, 846: 1-11 [46] Huang H, Liu N, Liao Y, et al. Platinum-containing compound platinum pyrithione suppresses ovarian tumor proliferation through proteasome inhibition[J]. J Exp Clin Cancer Res, 2017, 36(1): 79 [47] Zhao C, Chen X, Yang C, et al. Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases[J]. Oncotarget, 2017, 8(8): 13942-13956 [48] Chen X, Yang Q, Chen J, et al. Inhibition of Proteasomal Deubiquitinase by Silver Complex Induces Apoptosis in Non-Small Cell Lung Cancer Cells[J]. Cell Physiol Biochem, 2018, 49(2): 780-797
